Servier launches its first oncology treatment in the solid tumor field in Brazil

08/12/2020

Paris (France), December 8, 2020 – Servier do Brasil, a Servier Group affiliate, announced the arrival on the Brazilian market of its first oncology treatment in the solid tumor field.

This launch follows the obtention, by Servier do Brasil, of the market authorization delivered last May by the Brazilian Health Regulatory Agency (ANVISA).

“The availability of a new anti-cancer drug for patients in Brazil marks the strengthening of Servier’s oncology activities, with now a second major drug available for Brazilian patients,” stated Mathieu Fitoussi, Managing Director of Servier do Brasil.

Cancer is the second leading cause of death globally and was responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer.[1] Given the magnitude of worldwide therapeutic needs in oncology, the Servier Group has made oncology one of its strategic priorities, dedicating today 50% of Servier’s overall R&D budget[2] to oncology.

 

″The launch of an anti-cancer drug in Brazil marks our efforts to provide innovative cancer treatments for patients around the world, and this is another step towards our ambition to become a recognized and innovative player in oncology,” stated Emmanuel Pradère, Director of the Oncology Franchise at Servier. ″The major investment of the Group in the fight against cancer today translates into six treatments available to patients throughout the world and fifteen molecular entities in clinical development.″

 

Servier has been present for nearly 45 years in Brazil reaching a leading position in cardiology, hypertension, diabetes and chronic venous disease, in developing various activities, including research (Therapeutic Research Centre – ICTR), production and more recently generic activities (Pharlab).

 

Brazil is a strategic country where Servier has high expectations in the short term making available this year 5 new medicines to treat serious chronic cardiovascular diseases, as well as in the mid-term expecting to more than double the number of Brazilian patients benefiting from Servier treatments.

 

 

[1] Who: https://www.who.int/news-room/fact-sheets/detail/cancer

[2] Excluding generics